← Oncology Approval Tracker

FDA DECISION ·

Keytruda + chemotherapy

pembrolizumab with neoadjuvant chemotherapy, followed by adjuvant pembrolizumab · Merck

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients with high-risk early triple-negative breast cancer, using pembrolizumab with chemotherapy before surgery and pembrolizumab alone afterward.

LAMPGEN ANALYSIS

Why it matters

The regimen spans preoperative treatment and postoperative continuation in high-risk early disease.

What research teams should watch

Coordinate neoadjuvant cycles, surgery, pathology and adjuvant restart dates.

PRIMARY RECORDS

Sources